Scientists at Roche Holding AG’s (ROG.VX) biotechnology unit Genentech have found a way to get antibody-based therapies across a key barrier in the brain and deliver a payload of drugs that take aim at an elusive Alzheimer’s target.
They said the findings from two studies, reported on Wednesday in the journal Science Translational Medicine, could open the door to new treatments for diseases like Alzheimer’s, schizophrenia, Parkinson’s and even autism.
